Which TKI? An embarrassment of riches for chronic myeloid leukemia patients

Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program

Volumn 2013, Issue , 2013, Pages 168-175

  Hughes, Timothy ^a   White, Deborah ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4-METHYL-N-(3-(4-METHYLIMIDAZOL-1-YL)-5-(TRIFLUOROMETHYL)PHENYL)-3-((4-PYRIDIN-3-YLPYRIMIDIN-2-YL)AMINO)BENZAMIDE; DASATINIB; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE; TUMOR PROTEIN;

ANTAGONISTS AND INHIBITORS; ENZYMOLOGY; HUMAN; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; METABOLISM;

HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; NEOPLASM PROTEINS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; THIAZOLES;

EID: 84896727918     PISSN: None     EISSN: 15204383     Source Type: Journal    
DOI: 10.1182/asheducation-2013.1.168     Document Type: Review

References (0)